Alfacell's Combination Cancer Therapy
Chemotherapy failure due to multiple drug resistance may be overcome by using Alfacell's Onconase (RNase) in combination with vincristine, according to animal studies conducted by the US National Cancer Institute.
The researchers found that the combination of the two drugs had a synergistic effect on tumor kill, overcoming multiple drug resistance in a human colon cancer xenograft.
This follows in vivo studies, published in the Journal of the National Cancer Institute (June 5), which showed an increased median survival rate of 22 days in drug-resistant cancerous mice treated with the Onconase/vincristine combination, compared to controls.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze